Research Pipeline
What We're Working On
BellyMD isn't just a supplement company. We're building the clinical infrastructure for conditions the medical system hasn't prioritized.
George Washington University
Dr. Andrew Meltzer's lab identified the first blood-based biomarkers for CHS — immune and genetic signatures detectable from a simple blood draw. BellyMD secured the technology transfer to bring this diagnostic from academic research into clinical development.
Decades of Dismissal
No objective test. No targeted treatment. Patients told to 'just stop.' CHS meant ruling everything else out — with no path forward.
A Diagnostic Breakthrough
Dr. Andrew Meltzer's team at George Washington University identified unique immune and genetic biomarkers detectable in a simple blood sample — the first objective CHS diagnostic.
Technology Transfer
BellyMD secured the technology transfer partnership with GWU — bringing this diagnostic from the lab into clinical development.
Integrated Clinical Program
GWU's blood-based diagnostic is being validated within the BMD-001 trial — simultaneously advancing detection and treatment in one integrated program.
BMD-001
First CHS Therapeutic
BMD-001 is a proven experimental compound entering first-in-human randomized clinical trials for the treatment and management of Cannabinoid Hyperemesis Syndrome — designed specifically for patients where cannabis cessation is not a viable or chosen option.
This is the world's first therapeutic developed specifically for CHS, built on the understanding that patients deserve treatment options — not just advice to stop.
The only organization in the world advancing both CHS diagnostics and therapeutics in one integrated clinical program.
Fixed-Dose Combination Therapeutic
Early Development
A fixed-dose combination therapeutic targeting both CVS (Cyclic Vomiting Syndrome) and CHS is in early-stage development. These conditions share overlapping nausea-dominant phenotypes and may benefit from a unified treatment approach.
This program is in early development and has not entered clinical trials.
What's Next
Our research agenda is focused on conditions where patients have been underserved — where no objective diagnostic exists, where treatment options are limited, and where the gap between symptom burden and clinical attention is widest.
We're not announcing what's next until the science is ready. But the pattern is clear: identify the gap, build the evidence, and bring something real to patients who've been waiting.
Important Disclosures
BMD-001 is an investigational compound and has not been approved by the FDA or any other regulatory authority for the treatment of CHS or any other condition.
The GWU blood-based diagnostic is in development and has not received regulatory clearance. The associated research is pre-peer-review (preprint).
Dr. Andrew Meltzer is affiliated with George Washington University and is not employed by or affiliated with BellyMD.
Nothing on this page constitutes medical advice or a guarantee of future results. Clinical trial timelines are estimates and subject to change.